Prevention of endothelial dysfunction in patients with type 2 diabetes

Simultaneous use of chromium picolinate and vitamin D reconstruction or prevention of endothelial dysfunction in patients with type 2 diabetes by examining the pattern of changes in metabolic markers of oxidative stress, inflammation and endothelial dysfunction

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017052034038N1

Enrollment

Registered

2017-06-14

Start date

2017-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus. Diabetes mellitus

Interventions

Intervention 1: The second group: receiving 400 microgram of chromium picolinate daily for 6 months. Intervention 2: The third group: receiving vitamin D for 6 months, per week 50,000 IU. Interventio

Treatment - Drugs

The second group: receiving 400 microgram of chromium picolinate daily for 6 months

The third group: receiving vitamin D for 6 months, per week 50,000 IU

the first group: the control group received a placebo for 6 months.

fourth Group : receiving Vitamin D and chromium picolinate for six months, 50,000 units per week and 400 micrograms for per day, respectively.

Eligibility

Sex/Gender

All

Age

25 Years to 60 Years

Inclusion criteria

Inclusion criteria: (Inclusion criteria: patients with type 2 diabetes for a maximum of 5 years; 25 to 60 years ages; with metformin as a hypoglycemic medication) (Exclusion criteria: patients with Insulin injection; inflammatory diseases; kidney disease; liver disease; parathyroid disease; pregnancy and lactation; taking anticonvulsants and steroids; history of tobacco; the use of supplements and minerals ; patients with hypertension and hypothyroidism)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting blood sugar. Timepoint: Before and after the intervention. Method of measurement: KIT.;Oral glucose tolerance test. Timepoint: Before and after the intervention. Method of measurement: KIT.;Glycated haemoglobin (HbA1C). Timepoint: Before and after the intervention. Method of measurement: KIT.;Cholesterol of LDL. Timepoint: Before and after the intervention. Method of measurement: KIT.;HDL-C. Timepoint: Before and after the intervention. Method of measurement: KIT.;TRIGLYCERIDE. Timepoint: Before and after the intervention. Method of measurement: KIT.;TOTAL CHOLESTROL. Timepoint: Before and after the intervention. Method of measurement: KIT.;Tumor necrosis factor alpha (TNF-a). Timepoint: Before and after the intervention. Method of measurement: KIT.;Malondialdehyde (MDA). Timepoint: Before and after the intervention. Method of measurement: KIT.;Total thiols OF PROTIENS. Timepoint: Before and after the intervention. Method of measurement: KIT.;The total antioxidant capacity. Timepoint: Before and after the intervention. Method of measurement: KIT.;Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1). Timepoint: Before and after the intervention. Method of measurement: KIT.;Plasminogen activator inhibitor type 1 (PAI-1). Timepoint: Before and after the intervention. Method of measurement: KIT.;INSULIN. Timepoint: Before and after the intervention. Method of measurement: KIT.;CHROMIUM. Timepoint: Before and after the intervention. Method of measurement: KIT.;25(OH) D3. Timepoint: Before and after the intervention. Method of measurement: KIT.;CALCIUM. Timepoint: Before and after the intervention. Method of measurement: KIT.;PHOSPHOR. Timepoint: Before and after the intervention. Method of measurement: KIT.;Parathyroid hormone test. Timepoint: Before and after the intervention. Method of measurement: KIT.	—

Measure

Time frame

Fasting blood sugar. Timepoint: Before and after the intervention. Method of measurement: KIT.;Oral glucose tolerance test. Timepoint: Before and after the intervention. Method of measurement: KIT.;Glycated haemoglobin (HbA1C). Timepoint: Before and after the intervention. Method of measurement: KIT.;Cholesterol of LDL. Timepoint: Before and after the intervention. Method of measurement: KIT.;HDL-C. Timepoint: Before and after the intervention. Method of measurement: KIT.;TRIGLYCERIDE. Timepoint: Before and after the intervention. Method of measurement: KIT.;TOTAL CHOLESTROL. Timepoint: Before and after the intervention. Method of measurement: KIT.;Tumor necrosis factor alpha (TNF-a). Timepoint: Before and after the intervention. Method of measurement: KIT.;Malondialdehyde (MDA). Timepoint: Before and after the intervention. Method of measurement: KIT.;Total thiols OF PROTIENS. Timepoint: Before and after the intervention. Method of measurement: KIT.;The total antioxidant capacity. Timepoint: Before and after the intervention. Method of measurement: KIT.;Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1). Timepoint: Before and after the intervention. Method of measurement: KIT.;Plasminogen activator inhibitor type 1 (PAI-1). Timepoint: Before and after the intervention. Method of measurement: KIT.;INSULIN. Timepoint: Before and after the intervention. Method of measurement: KIT.;CHROMIUM. Timepoint: Before and after the intervention. Method of measurement: KIT.;25(OH) D3. Timepoint: Before and after the intervention. Method of measurement: KIT.;CALCIUM. Timepoint: Before and after the intervention. Method of measurement: KIT.;PHOSPHOR. Timepoint: Before and after the intervention. Method of measurement: KIT.;Parathyroid hormone test. Timepoint: Before and after the intervention. Method of measurement: KIT.

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactdr.Fatemeh Imanparast

Khomein University of Medical Sciences

fimaniran64@gmail.com+98 86 4622 6006

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026